netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Pemetrexed found 11 matches
Open monograph to display formulary status BNF Category
  Cytotoxic Drug Pemetrexed Malignant disease and immunosuppression - Antimetabolites - 08.01.03
  Amivantamab  (Rybrevant®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Pembrolizumab  (Keytruda®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA1060: Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer (08.02.04)
link in drug section NICE TA1158: Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer (08.01.05)
link in drug section NICE TA124: Pemetrexed for the treatment of non-small-cell lung cancer (08.01.03)
link in drug section NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma (08.01.03)
link in drug section NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer (08.01.03)
link in drug section NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer (08.01.03)
link in drug section NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (08.01.03)
link in drug section NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (08.01.05)


 
netFormulary